ESMO 2025: Phase III Trial of [177Lu]Lu-PSMA-617 Combined with ADT + ARPI in Patients with PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer (PSMAddition) Publicado 29 de Noviembre de 202500:14:31ver más
AUA 2025: Oncologic Outcomes and Conditional Survival of Patients Receiving Metastases-Directed Therapy for Prostate Cancer Recurrence After Radical Prostatectomy Detected by a Positive PSMA PET Publicado 29 de Noviembre de 202500:13:57ver más
EAU 2025: Metastatic Hormone Sensitive Prostate Cancer with a Deep Response to ADT plus ARPI: The Pros and Cons of De-escalation of Systemic Therapy Publicado 20 de Noviembre de 202500:18:03ver más
ESMO 2025: 3-Weekly Docetaxel 75 mg/m2 vs 2- Weekly Docetaxel 50 mg/m2 in Combination with Darolutamide + ADT in Patients with mHSPC – Results from the Randomised Phase 3 ARASAFE Trial Publicado 20 de Noviembre de 202500:13:09ver más
ASCO GU 2025: Which Patients with mHSPC Benefit More from Androgen Receptor Pathway Inhibitors? STOPCAP Meta-Analyses of Individual Participant Data Publicado 29 de Noviembre de 202500:18:02ver más
AUA 2025: Who Still Needs a Lymph Node Dissection with a Negative PSMA-PET? Results from the Michigan Urological Surgery Improvement Collaborative Publicado 29 de Noviembre de 202500:14:03ver más